Endo pain drug flunks a Ph2 test

A little more than two years after in-licensing a pain drug from Grunenthal, Endo Pharmaceuticals said today that the treatment failed a mid-stage, placebo-controlled study for lower back pain. Endo said it would complete its analysis of the data on axomadol and then decide how it would proceed with the program. Endo release

Suggested Articles

Immunic's lead asset beat placebo at reducing damage to myelin, which protects nerve fibers, in patients with relapsing multiple sclerosis.

The appointment sees Kobayashi switch from developing Dermira’s anti-IL-13 drug to advancing Aslan’s would-be rival.

Lilly has created customized mobile research units to run the clinical trial as the long-term care facilities lack experience running studies.